2014 Highlights: 5 most popular More Than Medicine topics

As the end of the year draws near, we took a close look at which recent posts (blog, Twitter, Facebook, Linked in, YouTube) had the most visits, clicks, likes, shares, etc. We thought the outcome was interesting and we figured maybe you would too. So, without any further delay, here are the top 5 topics we've discussed recently on More than medicine

#1 - Business for Social Responsibility Conference

Our CEO, Sir Andrew Witty, spoke at the 2014 Business for Social Responsibility Conference in New York in November. His speech focused on how transparency, transformation, and collaboration will help ensure long-term, sustainable commercial success while also meeting the needs of society. 

 

 

#2 - New satellite office in Boston

Anyone familiar with the Boston-Cambridge region will tell you it's home to a vibrant mix of ideas and scientists that make innovation thrive. As a science-led company, it made sense for us to have a base there, to be close to our current collaborators and meet new ones. So, in September, we opened our Kendall Square satellite office.

 

 

#3 - Escalating importance of antibiotic research

In September, we joined the President’s Council of Advisors on Science and Technology (PCAST) to formulate recommendations to address the growing concern around the rise of antimicrobial resistance. These recommendations fed into a new task force for combating antibiotic-resistant bacteria that will be chaired by the Secretaries of Defense, Agriculture, and Health and Human Services. 

We sat down with Kris Famm, Head of the Bioelectronics R+D Unit at GSK to understand how something the size of a grain of rice can latch on to a nerve and improve someone's health. The topic was featured by the New York Times in May and has continued to be an area of interest for us. 

 

 

#5 - Our role in expanding the fight against ebola

As the Ebola crisis continues, the global health community continues to rally together to find solutions. GSK and NIH announced in September that a new vaccine candidate is heading into clinical trials. GSK’s Vice President of Public Policy, Donna Altenpohl, appeared on BioCentury TV to discuss this hopeful development and the United States’ response to Ebola.